CoreMedic GmbH
CoreMedic GmbH is a German clinical-stage medical technology company developing the ChordArt transcatheter mitral valve repair system for patients with mitral valve regurgitation ineligible for open-heart surgery. The pre-revenue firm targets leading European cardiac surgery centers and is pursuing CE marking.
- Company typePrivate
- Founded2012
- HeadquartersRadolfzell Am Bodensee, Germany
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What CoreMedic GmbH does
CoreMedic GmbH is a private medical technology company developing transcatheter devices for the treatment of heart valve diseases, with a primary focus on mitral valve regurgitation (MR). The company originated as a 2012 spin-out from the Heart Center of the University of Bern, Switzerland, became operationally independent in 2014, and relocated to Radolfzell am Bodensee, Germany in 2017 to anchor itself in the Tuttlingen medical technology cluster. Its lead product, the ChordArt Transcatheter Mitral Valve Repair (TMVr) System, is a catheter-based device that replaces damaged or elongated mitral valve chords through a minimally invasive transfemoral, transseptal route, eliminating the need for open-heart surgery. The system is positioned as a first-line treatment for Primary Mitral Regurgitation and is described as the world's first transcatheter chordal replacement technology, supported by five-year clinical follow-up data demonstrating sustained safety, effectiveness, and structural durability of the implant.
The company operates a B2B go-to-market model targeting leading cardiac surgery centers and heart valve centers of excellence, primarily in Europe. Revenue is generated through hardware sales of the ChordArt system and adjacent professional services including physician training and proctoring. CoreMedic is currently in clinical development: the CHAGALL first-in-man trial is enrolling up to 40 patients across six European centers, and the company is pursuing CE marking for European market entry. The firm holds EN ISO 13485:2016 certification and is backed by institutional healthcare investors SHS Capital (since 2017) and MIG Capital (Series B extension in February 2025). Management and supervisory teams include veterans of Medtronic, Edwards Lifesciences, INVATEC, Abbott, and Jomed, with established KOL relationships across interventional cardiology and cardiac surgery in Europe.
CoreMedic GmbH firmographics
Firmographics- Name
- CoreMedic GmbH
- Legal name
- CoreMedic GmbH
- Website
- https://coremedic.de
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CoreMedic GmbH is a German clinical-stage medical technology company developing the ChordArt transcatheter mitral valve repair system for patients with mitral valve regurgitation ineligible for open-heart surgery. The pre-revenue firm targets leading European cardiac surgery centers and is pursuing CE marking.
- Ownership category
- akta.pro rank
CoreMedic GmbH industry classification
Industry- Product category
- Transcatheter Mitral Valve Repair Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)
Keywords
Where CoreMedic GmbH is headquartered
LocationHeadquarters
- HQ city
- Radolfzell Am Bodensee
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
CoreMedic GmbH business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- ChordArt TMVr System Sales: CoreMedic generates revenue through the sale of its ChordArt transcatheter mitral valve repair system, including the implant and catheter delivery components. The system is sold to cardiac surgery centers and hospitals for use in treating mitral valve regurgitation patients.
- Professional Services and Training: The company provides physician training, proctoring services, and clinical support as part of its commercial roll-out, helping cardiologists and cardiac surgeons adopt the technology.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
CoreMedic GmbH product offering
Product offeringCore offering
CoreMedic develops and manufactures the ChordArt Transcatheter Mitral Valve Repair (TMVr) System, a catheter-based medical device designed to replace damaged or ruptured mitral valve chords through a minimally invasive transfemoral, transseptal percutaneous procedure. The system is sold to cardiac surgery centers and heart valve centers of excellence as a first-line treatment alternative to open-heart surgery for patients with primary mitral regurgitation.
Product overview
CoreMedic GmbH offers a single unified product — the ChordArt Transcatheter Mitral Valve Repair (TMVr) System. This catheter-based device is designed to replace ruptured or elongated mitral valve chords through a minimally invasive percutaneous approach, providing an alternative to traditional open-heart surgery for patients with mitral valve regurgitation. The system enables chordal replacement via transfemoral, transseptal delivery, reducing patient trauma, procedure complexity, and recovery time compared to surgical gold standard.
Differentiator
Problem solved
Functional benefit
Products and services
- ChordArt TMVr-System A transcatheter mitral valve repair (TMVr) system designed to replace damaged mitral valve chords through a minimally invasive percutaneous procedure via transfemoral, transseptal route, enabling treatment of patients with mitral valve regurgitation who are not eligible for conventional open-heart surgery.
Quantifiable outcome
- Technical success achieved in 100% of first 5 patients with MR reduction to no or trace residual MR (<1+/4+)
- +5 more outcomes
Companies that use CoreMedic GmbH
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles1 record
CoreMedic GmbH technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
CoreMedic GmbH partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- InnoRa GmbHcoreCoreMedic entered a strategic partnership with InnoRa GmbH, a German medical device company headquartered in Berlin specializing in cardiovascular devices since 2001. InnoRa contributes over 20 years of experience in cardiovascular device development and clinical trial translation. The partnership includes an undisclosed investment by InnoRa, with Professor Bruno Scheller (co-founder of InnoRa and renowned expert in interventional cardiology) joining CoreMedic's Supervisory Board.
- Clinical Advisors and KOL NetworkcoreCoreMedic has assembled a network of internationally renowned clinical advisors including Prof. Thierry Carrel (cardiac surgeon with 700+ publications), Prof. Bruno Scheller (interventional cardiology expert), Prof. Maurizio Taramasso, Prof. Alberto Weber (Founder and CMO), and Prof. Rolf Vogel. These key opinion leaders provide scientific and clinical expertise and support the development and adoption of the ChordArt technology.
Scale indicators5 records
Recent moves9 records
Expansion highlights6 records
CoreMedic GmbH competitors and assessment
Company assessmentDirect peers
- Abbott: Abbott's MitraClip is the established market leader in transcatheter mitral repair, and the Tendyne system targets transcatheter mitral replacement — directly competing with CoreMedic's ChordArt for the same patient population and cardiology customer base. Abbott's installed-base advantage in catheter-based structural heart interventions makes it the most consequential incumbent.
- NeoChord: NeoChord develops the NeoChord DS1000 system for beating-heart mitral chordal replacement, the closest technology analog to ChordArt's artificial chord replacement approach. While NeoChord is delivered surgically (transapical) rather than percutaneously, both companies pursue chordal replacement for degenerative MR and target cardiac surgery centers.
- Edwards Lifesciences: Edwards Lifesciences markets the PASCAL and PASCAL Ace transcatheter mitral valve repair systems, the most direct competitor to CoreMedic's ChordArt in the transcatheter chordal/leaflet repair space. Edwards also sets the bar for transcatheter heart valve trial design and commercialization, and Jodi Akin (CoreMedic's Chair) led seminal global trials and approvals of transcatheter heart valve therapy at Edwards.
Emerging players
- InnovHeart: InnovHeart is developing the saturn TMVR system for transcatheter mitral valve replacement. It targets the same structural-heart customer base and MR patient population as CoreMedic with a replacement-focused approach.
- Cardiac Dimensions: Cardiac Dimensions develops the Carillon Mitral Contour System, a transcatheter annuloplasty device for functional mitral regurgitation. It targets an overlapping patient population and customer base (interventional cardiologists and heart teams) with a different but adjacent transcatheter mitral repair mechanism.
- HighLife Medical: HighLife Medical is developing a transcatheter mitral valve replacement system using a transseptal, transapical valve placement approach. Comparable European medtech with parallel TMVR development and similar regulatory pathway dynamics.
- Mitralign: Mitralign developed transcatheter annuloplasty systems for functional MR, directly competing for the same heart-failure MR patient segment with a percutaneous approach. Comparable mid-stage transcatheter mitral repair player with similar clinical-trial-stage commercialization pathway.
- 4C Medical Technologies: 4C Medical is developing the AltaValve system for transcatheter mitral valve replacement (TMVR), addressing mitral regurgitation with a supra-annular implant design. Competitor for the same MR patient population served by CoreMedic, though with a replacement rather than repair approach.
Broad incumbents
- Medtronic: Medtronic is a broad cardiovascular incumbent with a structural heart portfolio (including Intrepid TMVR) and deep relationships with cardiac surgery centers. Multiple CoreMedic founders held leadership roles at Medtronic and Invatec (acquired by Medtronic), positioning Medtronic as both a talent feeder and potential strategic acquirer.
- Boston Scientific: Boston Scientific acquired Acotec (co-founded by CoreMedic co-founder Silvio Schaffner) in 2022 for its drug-coated balloon portfolio and is active in structural heart via its Watchman franchise. As a broad incumbent in interventional cardiology, Boston Scientific is both a potential strategic acquirer of CoreMedic and an indirect competitor in structural heart catheter-based therapies.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CoreMedic GmbH social profiles
Digital presenceCoreMedic GmbH compliance and trust
Trust signalCompliance1 record
CoreMedic GmbH financial estimates
Financial estimateRevenue estimate
Valuation estimate
CoreMedic GmbH leadership team
Management profileNumber of profiles
Profiles12 records
CoreMedic GmbH funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CoreMedic GmbH M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CoreMedic GmbH
What does CoreMedic GmbH do?
CoreMedic develops and manufactures the ChordArt Transcatheter Mitral Valve Repair (TMVr) System, a catheter-based medical device designed to replace damaged or ruptured mitral valve chords through a minimally invasive transfemoral, transseptal percutaneous procedure. The system is sold to cardiac surgery centers and heart valve centers of excellence as a first-line treatment alternative to open-heart surgery for patients with primary mitral regurgitation.
Is CoreMedic GmbH a public or private company?
CoreMedic GmbH is a private company. It is classified as venture growth investor backed and is currently operating.
When was CoreMedic GmbH founded?
CoreMedic GmbH was founded in 2012. It employs 1 to 10 people.
Where is CoreMedic GmbH based?
CoreMedic GmbH is headquartered in Radolfzell Am Bodensee, Germany, in the Europe region.
How does CoreMedic GmbH make money?
Two revenue lines are on record. ChordArt TMVr System Sales are the primary driver. The others are professional Services and Training.
Who are CoreMedic GmbH's main competitors?
Direct peers on record are Abbott, NeoChord and Edwards Lifesciences. Emerging players are InnovHeart, Cardiac Dimensions, HighLife Medical, Mitralign and 4C Medical Technologies. Broad incumbents are Medtronic and Boston Scientific.
Does CoreMedic GmbH have an API?
No public API is recorded for CoreMedic GmbH.
What industry is CoreMedic GmbH in?
CoreMedic GmbH's product category is Transcatheter Mitral Valve Repair Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 339112 and its SIC code is 3841.